Cell MedX (Cell MedX) Growth Rank : 0 (As of Jun. 10, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Cell MedX Growth Rank?

Cell MedX has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Cell MedX Growth Rank Related Terms

Thank you for viewing the detailed overview of Cell MedX's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Cell MedX (Cell MedX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cell MedX Corp (OTCPK:CMXC) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

123 W. Nye Lane, Suite 446, Carson City, NV, USA, 89706

Website

https://www.cellmedx.com

Cell MedX Corp is an early stage development company focused on the discovery, development and, commercialization of therapeutic products for patients with diseases such as diabetes, by developing technologies to help manage the illness and related complications. The company's product portfolio consists of electromedical technologies, ebalance, and others.

Executives

Richard Jeffs	10 percent owner	FLAT 7, 6 ENNISMORE GARDENS, LONDON X0 SW7 1NL
Dwayne Yaretz	director, officer: Chief Executive Officer	SUITE 1050 WEST PENDER STREET SUITE 2250, VANCOUVER A1 V6E 3S7
Bradley S Hargreaves	10 percent owner	904-1616 BAYSHORE DR, VANCOUVER A1 V6G3L1
Frank Mcenulty	director, officer: CEO, CFO, Treas., Sec	4182 N. VIKING WAY, SUITE 216, LONG BEACH CA 90808-1475
Joao Dacosta	director, officer: COO	#810 - 789 WEST PENDER STREET, VANCOUVER A1 V6C 1H2
George Adams	director	7535 CONSERVATION ROAD, GUELPH A6 N1H6J1
Terrance George Owen	director, officer: CEO	635 FOURTH LINE (UNIT 1), OAKVILLE A6 L6L 5BO
John David Sanderson	officer: Chief Medical Officer	9 ISLANDVIEW, IRVINE CA 92604
Yanika S Silina	officer: CFO, Treasurer and Secretary	789 WEST PENDER STREET, UNIT 810, VANCOUVER A1 V6C 1H2
Jean M Arnett	10 percent owner	121 - 3989 HENNING DRIVE, BURNABY A1 V5C 6P8
Ean Kremer	director, officer: Chief Technology Officer	C/O PLANDEL RESOURCES, INC., 4575 DEAN MARTIN DRIVE, STE. 2206, LAS VEGAS NV 89103

Cell MedX (Cell MedX) Headlines

From GuruFocus

Cell MedX Insider Buys 22,500 Shares

By Kyle Ferguson Kyle Ferguson • 11-11-2016